WuXi Biologics subsidiary WuXi Vaccines has agreed to sell its vaccine manufacturing facility in Dundalk, Ireland, to MSD for approximately $500m. Expected to close in the first half of 2025, the deal ...

The Dundalk site was WuXi's first manufacturing investment in Europe and the company’s first investment of this scale outside of China ...

MSD has expanded its presence in Ireland with an agreement to buy a vaccine manufacturing facility from Chinese biotech WuXi Biologics for around €500 million (around $520 million). The plant in ...

Pharma giant MSD is buying the Dundalk-based vaccines plant of Chinese rival Wuxi in a €500 million deal. Wuxi invested €200 million in 2019 to build the plant, which currently employs 200 ...

The pharmaceutical firm MSD is buying out the WuXi Vaccines manufacturing plant in Dundalk, in a €500m deal. The American company says that in addition to the 150 jobs at the Dundalk facility ...

News that pharmaceutical company MSD Ireland has acquired the WuXi Vaccines manufacturing facility in Dundalk has been ...

announced on 06 January the sale of its WuXi Vaccines facility in Ireland to MSD International, a subsidiary of Merck & Co. for approximately 500 million USD. Arne Dedert/dpa WuXi Biologics ...

Pharmaceutical firm MSD has agreed a deal to buy the WuXi Vaccines manufacturing facility in Dundalk, Co Louth as part of its long-term plans in Ireland. MSD said the deal is worth €500m and ...

Wuxi Biologics (Cayman) ( (HK:2269) ) has provided an announcement.

WuXi Biologics subsidiary WuXi Vaccines has agreed to sell its vaccine manufacturing facility in Dundalk, Ireland, to MSD for approximately $500m. Expected to close in the first half of 2025 ...